Seeking Alpha

Soligenix gets orphan designation for SGX94

Soligenix (SNGX.OB) scores an orphan designation for the innate defense regulator SGX94 in patients with acute radiation syndrome.

In clinical models, the drug minimized damage to the skin and gastrointestinal tract, and "enabled clearance of infection as a result of damage to the hematopoietic system." (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs